Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Scientists at EPFL and Johns Hopkins uncover the central role of an enzyme in controlling prostate cancer subtypes and ...

Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology ...

As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., ...

Genetics play a role in low testosterone for some men, but underlying causes vary widely. Many genes influence testosterone ...

Clascoterone 5% topical solution, an anti-androgen that targets the hair follicle androgen receptor without measurable ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that ...

Ground-breaking new research has found for the first time that the friendly bacteria in the gut can be enhanced to help slow ...

Worried about irregular periods and fertility? Get expert insights from Kozhikode Gynaecologist Dr. Bala Guhan. Bust myths & ...

Clinical-stage biotechnology company Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) on Wednesday revealed interim data from an ...